Prot# NU 15C03 - A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Glioblastoma with Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination To Determine Immunologic Changes From Treatment

Project: Research project

StatusActive
Effective start/end date6/13/167/1/22

Funding

  • AstraZeneca Pharmaceuticals LP (Prot# NU 15C03)